Clarivate

Cortellis Competitive Intelligence

特定企業のプロフィール(注力する疾患と開発ステージ、ポートフォリオ等) を確認する

Cortellis Competitive IntelligenceのCompany Reportには、過去のパートナリングや吸収合併の歴史、保有するポートフォリオや開発関連特許の一覧、専門性のある技術領域や注力している疾患など、業務提携を検討する上で企業評価の 参考となる情報が収録されています。

本資料ではUSに拠点を置くAkcea Therapeutics Incを例に、Cortellisに収録されている企業レポートを解説します。

1. 検索ボックスに企業名を入力し検索を実行します。検索結果画面左のレポートタイプにて、Companiesが選択されているかご確認ください。Akcea社のレコード名をクリックし、レポートを展開します。

Cortellis [®]	All - akcea		Index C	Full Text Q	Explo	re 👻				
	Advanced search Structure search Search history									
<back forward="" =""></back>	Search Results			c	Related Content	💕 Save a	and Ale			
	3 results found for index Search for	the search term 'akcea'				First	Previou			
Report Type	Results Perpage: 25 🗸 So	rt by: Relevance	♥ ♥ Orde	r Columns		1	View			
Show selected only	Company Name	Parent Company Name	Organization Type	Key Technologies	Field of Activity		Countr			
Broker Bernerth (1040)		Filters : [0]	Filters : [0]	Filters : [0]	Filters : [0]		Filters :			
Clinical Trials (51)	Akcea Therapeutics Inc	Ionis Pharmaceuticals Inc	Organization Sub-Type : Company	Antibody fragment; Antibody; Imaging; Immunodetection; Monoclonal antibody; Peptide	Biologics		US			
Companies (3) Conferences (26)				Transgenie mouse						
Deals (10)										
Disease Briefings (2)	Akcea Therapeutics UK Ltd	Ionis Pharmaceuticals Inc	 Parent Com 業の組合社友 	pany Nameはれ ·テレキす 木事(英案対象の1 列でけれる:	-	UK			
Drugs (7)			木の杭云江で	.小しよう。本手		-				
Event Transcripts (219)			社の親会社で	あるIonisが記載	されています。	,				
Literature (7)										
Patents (26)	Ionis Pharmaceuticals Inc	Ionis Pharmaceuticals Inc	Organization Sub-Type :	Biological therapeutic;	Pharmaceuticals		US			
Press Releases (342)	-		Company Company Type : Public Company Size : Medium	Oligonucleotide antisense; Subcutaneous formulation; Parenteral formulation						
Regulatory (173)			and a second second	unspecified; RNA antisense;						

2. レポート画面左側のタブからCompany Profileを選択し、企業の変遷を確認できます。Company Profileは合併、 買収、スピンオフといった企業の変遷について、編集員が各ソースを参考に内容をサマライズして収録します。

Back Forward >	Company Report
kcea Therapeutics Inc	各テキストの冒頭は関連ニュースの日付で始まり、最後にはソース番号が記載されま
Snapshot	Highlight Search Terms & Synonyms < Pn
Latest Press Releases	COMPANY PROFILE
Latest Event Transcripts	SUMMARY
Broker Research Reports	Akcea Therapeutics Inc is an affiliate of Isis Pharmaceuticals which is focused on the development and commercialization of the drugs in tsis' lipid franchise.
	ACQUISITIONS AND SPIN-OFFS
Company Profile	In October 2020, Ionis Pharmaceuticals announced the successful completion of its transaction to acquire 100% ownership of Akcea Therapeutics [2339467].
Funding	In August 2020, Junis signed an agreement with the company to acquire all Alexa's share that it did not already own, approximately 24%, for \$18.15 per share in cash. The transaction area exceeded to clears in the bearth custer of a 2020 12312811. In Orthon 2020. Line is completed acquirillon of Alexa 123246731
Financials	In September 2017, the company and lonis (formerly Isis) established a wholly owned Canadian subsidiary, Akcea Therapeutics Canada inc [1059548].
Company Contacts	LICENSING AGREEMENTS
Subsidiary Companies	In August 2020, Ionis Pharmaceuticals and its affiliate Akcea Therapeutics entered into a definitive agreement under which Ionis acquired all of the outstanding shares of Akcea common stock that was not already own, approximately 24%, for \$18.15 per share in cash [2312894].
Drug Sales and Forecasts	FINANCIAL
Drugs	In July 2017, the company announced the pricing of its initial public offering of 15,625,000 shares of common stock at a public offering price of S8 per share, for gross proceeds of \$125 million. At that time, Akcea had granted the underwriters a 30-day option to buy up to 2,443,750 additional shares of common stock at the public offering price, less
Deals	underWinung discount and commissions, to cover over-altorments, it aliy, necessi sharles were appected to begin trading on the MysLAQ ulobal select Maintee on Juny 14, 2017 under the symbol "ArXEC" The offering was expected to close on July 19, 2017, subject to customary closing conditions, in addition, Revarite Pharma hard agreed to purchase S50 purchase S50
Clinical Trials	offering price. The closing of the initial public offering was placement concurrent with compression of works as much placement (1945072); later that month, the initial public offering was not conditioned upon the closing of the concurrent private placement (1945072); later that month, the initial public offering was closed. The access forced from the offering were \$143.8 million. Novariti Pharma purchased \$50.0 million
Patents	of Akcea's common stock in a separate private placement. Akcea's common stock was listed on the NASDAQ Global Select Market under the symbol "AKCA" [1946114].
Change History	In March 2017, the company filed a registration statement on Form S-1 with the SEC, for the proposed public offering of its common stock. At that time, the company applied to list its common stock on the Nasdag (lobal Market under the trading symbol XA
Sources	expected to be between \$12.00 and \$14.00 per share [13:6029] 「百子表記の数子はアキストソースとのにし、アクセス可能です

🗘 Clarivate

3. Drugタブを選択すると開発ポートフォリオを疾患領域および開発ステージ別にチャート表示できます。 チャート内をクリックすると該当する医薬品レポート一覧へアクセスします。



4. 二段目のチャートでは開発品のステージ分布を表示します。ポートフォリオの開発ステージごとの分布から後期開発品に注力しているのか、前臨床段階の研究開発に注力しているのか、パートナリングを検討する上での企業特徴をクイックに確認可能です。



5. Deal、Clinical Trials、Patentの各タブを選択すると、ライセンスタイプ別のディール件数と一覧へのアクセス、対象疾患・Phaseごとの試験数とその一覧へのアクセス、疾患に紐づけた特許数一覧とそれらへのアクセスが可能になります。

Akcea Therapeutics Inc						
Snapshot	Highlight Search Terms & Synonyms < Previous Next >					
Latest Press Releases	DEALS					
Latest Event Transcripts	Agreement Type	Tar	Target (Principal Company) Active Inactive		Acquirer (Partner Company) Active Inactive	
Broker Research Reports		Ac				
Company Profile	Drug - Development/Commercialization License	1	0	1	0	2
Funding	Drug - Manufacturing/Supply	0	0	2	0	2
Financials	Drug - Commercialization License	1	0	0	0	1
Company Contacts	Drug - Funding	1	0	0	0	1
Subsidiary Companies	Technology - Other Proprietary	0	0	1	0	1
Drug Sales and Forecasts					View deals	as a results li
Drugs						
Deals	Deal Asset Type		Principal Active Inactive		Partner e Active Inactive	
 Agreement Type 						
Asset & Transaction Type	+ Product	5	5 0	7	0	12
Clinical Trials	Capital(Grants/Loans/Equity Inv./ Royalty buyouts)	1	1 0	0	0	1
Patents	+ Service	0	0	1	0	1

【製品に関する問い合わせ】 クラリベイト カスタマーケア (<u>ts.support.jp@clarivate.com</u>)

© 2021 Clarivate. Clarivate and its logo, as well as all other trademarks used herein are trademarks of their respective owners and used under license.